Jinmatrics Secures U.S. Patent for Gene Delivery Platform 'GM-CAD1'

Jinmatrics has obtained a U.S. patent for the core technology of its gene delivery vector platform, 'GM-CAD1'.

According to Jinmatrics on October 6, GM-CAD1 is an intelligent gene delivery platform manufactured by manipulating viral vectors using artificial intelligence (AI)-based design technology. The platform has achieved enhanced safety by eliminating viral pathogenicity and the potential for proliferation within the human body. In addition, it features reduced immunogenicity of the vector itself and maximized efficiency for delivering target genes.

The GM-CAD1 vector platform induces a strong immune response in the body to the loaded target gene. This enables the effective production of antibodies against the target gene antigen and induces an immune response that selectively destroys only the target cells expressing the antigen, making it widely applicable for the development of anticancer drugs, gene therapies, and vaccines.

Previously, Jinmatrics validated the efficacy of the GM-CAD1 platform in animal therapeutic models for cervical cancer and herpes zoster. In particular, the herpes zoster vaccine demonstrated more than three times the therapeutic effect compared to existing alternatives, and in February, based on these results, Jinmatrics secured domestic patent registration for GM-CAD1.

Seokjun Kim, Vice President of Jinmatrics, said, "With this newly granted U.S. patent, we have further strengthened the global intellectual property (IP) base of GM-CAD1," adding, "Moving forward, we will continue to develop a diverse range of pipelines using the core GM-CAD1 platform and will actively pursue global partnerships."

This content was produced with the assistance of AI translation services.